Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.

1. Innovative Transdermal
Technologies

2. Table of Contents
1
C
o
m
p
a
n
y
H
i
s
t
o
r
y
&
O
r
g
a
n
i
z
a
t
i
o
n
3
A
V
E
R
S
A
4
P
u
b
l
i
c
P
r
o
f
i
l
e
N
T
R
B
S
u
b
s
i
d
i
a
r
i
e
s
a
n
d
C
a
p
a
b
i
l
i
t
i
e
s
2
2

3. Company History &
Organization
Creating Products to meet the needs of
Physicians, Patients and Payers (the 4 P’s)
1

4. Company Timeline
2012
Nutriband Ltd. Founded in
Dublin, Ireland
Research conducted on
Transdermal technologies
in healthcare and
pharmaceutical space.
Business plan developed.
2012-2015
2016
Nutriband Inc.
established in Orlando,
FL. Acquires Nutriband
Ltd. (Ireland)

5. 2018
2020
Nutriband Inc.’s Abuse
Deterrent Patent filed by its
subsidiary 4P Therapeutics not
granted and issued in Europe,
UK, Japan, Korea, Australia,
Russia, Mexico with prosecution
continuing in US, Canada and
China.
Nutriband Inc. Acquires 4P
Therapeutics for $1.9MM paid in
Company Stock and Cash. 4P
Therapeutics Abuse Deterrent
technology becomes the Lead product
in Nutriband Inc.’s pipeline
2016
Nutriband Inc. files Form
10 with SEC, lists on OTC
market.

6. 2020
December – Nutriband Inc. Signs
Exclusive License Agreement with
RAMBAM Hospital Group for its
Closed System Transfer Device
2020
Nutriband Inc. acquires
Pocono Coated Products
Topical Transdermal
manufacturing Division and
Active Intelligence LLC for
$7.5MM in Company Stock
and Cash. Pocono
Pharmaceuticals established
as a subsidiary.
2021

7. Organizational Chart
CEO: Gareth Sheridan
Core Objective: Develop a transdermal abuse deterrent technology for
Fentanyl patches, called AVERSA. With FDA approval AVERSA will
revolutionize the safety standard for opioid based medications and save
countless lives per year. Follow on projects include transdermal delivery of
peptides and proteins targeting the Diabetes market
Core Objective: 4P Therapeutics is a clinical subsidiary of Nutriband
Inc. (NTRB) focused on the research and development of novel drug
delivery technologies and therapeutics. 4P develops products that meet
the needs of patients, physicians and payers.
Core Objective: Leverage our existing transdermal technology to bring
new & innovative products to the market.
Division Head: Dr. Alan Smith
Division Head: Tyler Overk
Division Head: Michael Myer
Core Objective: Ensure the delivery of tailored topical/transdermal
products and solutions designed to meet our partners needs.

8. Capabilities
● Contract Manufacturing
(Pocono)
● Testing and Release (Pocono)
● Quality Systems (Pocono / 4P)
● R&D / Clinical Development
● Nutriband Core Pipeline
2

9. 460,000,000+
9
Topical / Transdermal Patches Manufactured to Date
Average annual growth rate of 60% (2018-2021)
Manufacturing

10. 1MM Patches
1.25”x1.25” patch
10
Over 250,000 Kinesiology Tape Strips 2”x10” (12,500 rolls w/20 strips)
Larger patch daily output is over 450,000 (3”x5”)
Daily Coating Capacity

11. Research & Development
4P Therapeutics:
The company has capabilities for developing
pharmaceutical products from pre-clinical testing
to clinical manufacturing and early stage clinical
development (Phase I/II). A key company focus and
area of expertise is in the development of
transdermal products for currently injected
compounds, including proteins, peptides,
macromolecules and biologics. Transdermal
delivery of commercially available drugs or biologics
that are typically delivered via injection has the
potential to improve safety, efficacy and
therapeutic outcomes associated with these
treatments

12. Core Prescription Pipeline
Exenatide
● Dermal ablation
technology to deliver
peptides.
● Indication for type 2
Diabetes.
AVERSA®:
● Abuse Deterrent
technology for opioid
based medications
● Chonic Pain
● TDS Delivery
● Model to be proven
with Fentanyl market.
● Applications range to all
potentially harmful or
abusable Trandsdermal
and topical medications.
FSH
● Dermal ablation technology
applied to FSH for injection
free delivery.
● Indication for Fertility
treatment

13. AVERSA overview
3

29. Public Profile
NTRB
4

30. Stock symbol: NTRB
Trading Market: OTCQB
As of Feb 8, 2021

32. Partners and
Customers Served
1
6
NTRB Locations
Transdermal Patches/
partners / customers